A Phase 1, Open-label, Single Dose, Parallel-cohort Study To Evaluate The Pharmacokinetics Of Palbociclib (Pd-0332991) In Subjects With Impaired Hepatic Function
Phase of Trial: Phase I
Latest Information Update: 10 Nov 2016
At a glance
- Drugs Palbociclib (Primary)
- Indications Breast cancer; Colorectal cancer; Glioblastoma; Liposarcoma; Malignant melanoma; Mantle-cell lymphoma; Multiple myeloma; Non-small cell lung cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Pfizer
- 01 Nov 2016 Status changed from recruiting to completed.
- 04 Oct 2016 Planned End Date changed from 1 Sep 2016 to 1 Nov 2016.
- 04 Oct 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Nov 2016.